ArticleMolecular biology reports2026
Pharmacological evaluation reveals distinct anti-proliferative and migration-associated effects of curcumin analogues B-143 and B-155 in ovarian cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe elevated mortality associated with ovarian cancer arises from delayed detection, recurrent disease, and the rapid emergence of chemoresistance. This study assesses the anticancer efficacy of two synthetic curcumin analogues, B-143 and B-155, in comparison to natural curcumin, employing SKOV3 ovarian cancer cells as the experimental model.
objectiveThe aim of this study was to determine whether structural alterations to the analogues enhanced their functional performance. METHODS AND
resultsThrough assays assessing cytotoxicity, cell-cycle distribution, apoptosis, and migration, the findings revealed that B-155 exhibited significantly greater cytotoxicity compared to curcumin and B-143, which was associated with G2/M cell-cycle arrest and increased apoptosis. Furthermore, both B-155 and curcumin effectively suppressed SKOV3 cell migration, whereas B-143 displayed minimal effects. Network pharmacology analyses predicted that B-143 and B-155 interact with overlapping yet distinct angiogenesis- and metastasis-associated signaling networks, suggesting potential associations with multiple signaling pathways relevant to ovarian cancer. Moreover, RT-qPCR reveals curcumin consistently downregulated the expression of genes linked to epithelial-mesenchymal transition (EMT) and cellular stress, whereas B-143 and B-155 displayed only partial adaptive responses in several angiogenesis and metastasis transcription markers. To further explore the molecular basis of B-155 activity, molecular docking and molecular dynamics simulations were performed using MAPK14 (p38α MAPK) as a candidate target. Computational analyses demonstrated favorable binding of B-155 within the MAPK14 ATP-binding pocket and stable protein-ligand complex formation throughout a 100 ns simulation.
conclusionB-155 demonstrated more significant anticancer activity than B-143, suggesting superior structural change-enhanced effectiveness. This research highlights the influence of structural modifications on curcumin's biological activity, supports B-155 as a promising curcumin analogue for further investigation with anti-proliferative and migration suppressive properties, and emphasizes the need to incorporate both phenotypic and network-level assessments together with structural interaction analyses in curcumin-based drug development for ovarian cancer.
Indexed as
Identifiers
42550311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.